Given the often limited patient acceptance of chemotherapy, there is currently no international consensus on the efficacy and safety of rechallenging with an EGFR-TKI following EGFR-TKI-induced ILD.<h4>Case summary</h4>We report the case of a 73-year-old male with stage IV lung adenocarcinoma carrying an EGFR exon 19 deletions (Ex19del) mutation, who received first-line osimertinib at 80 mg daily. The gene discussed is EGFR; the disease is interstitial lung disease.